Long-term safety study of HRS-1893 for hypertrophic cardiomyopathy
Treatments studied
Part of Heart & circulation clinical trials.
This study tests the long-term safety of the drug HRS-1893 in people with hypertrophic cardiomyopathy who have already been in a previous HRS-1893 study. It helps doctors learn more about how safe the drug is over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have hypertrophic cardiomyopathy and have completed a previous study with HRS-1893.
- Women who can become pregnant must have a negative pregnancy test before starting and agree to use birth control during the study and for 3 months after the last dose.
- Men with partners who can become pregnant must agree not to donate sperm and to use birth control during the study and for 3 months after the last dose.
- You must understand the study and sign a consent form to participate.
- You cannot have had coronary artery disease (blocked heart arteries over 70%) or a heart attack before.
- You cannot have had fainting or dangerous fast heart rhythms in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage safety test of a new experimental drug called HRS-5765 in people without serious health conditions. Researchers want to make sure the drug is safe and understand how your body processes it.
This study tests an investigational medicine called HRS9531 for people with atherosclerotic cardiovascular disease (a buildup of plaque in the arteries that can lead to heart attacks and strokes). The trial aims to see if the medicine helps reduce risks in this condition.
This trial tests a new drug called HRS-1893 for people with heart failure with preserved ejection fraction (HFpEF). It aims to see if the drug can improve symptoms and quality of life.
This trial compares a new study drug (BHB-1893) with a standard heart medication called metoprolol to see which one better improves symptoms in people with obstructive hypertrophic cardiomyopathy. If you join, you will be randomly assigned to receive either the study drug or metoprolol, and your symptoms and heart function will be monitored over time.
This study tests an investigational drug called HRS-1780 for people with high blood pressure that is not well controlled or is resistant to treatment. The purpose is to see if it can lower blood pressure more effectively than current options.
This is an early-stage safety study of an experimental drug called HRS-7156 in people with no serious health conditions. Researchers will monitor how your body tolerates the drug and how it moves through your system.
Hear when a new Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.